title: [Differentiated thyroid cancer].
abstract: Thyroid carcinoma is a rare and heterogeneous disease. Initial therapy and follow-up has to be adjusted to the individual risk for an excellent vs. poor prognosis. Differentiated thyroid cancer has a very high cure rate and is treated by surgery, usually followed by radioiodine ablation. Depending on the response to initial therapy the risk for persisting or recurrent disease should be re-evaluated. Continued TSH suppressive levothyroxine therapy is only recommended in high-risk patients. In contrast, metastatic radioiodine-refractory thyroid cancers have a poor prognosis and may benefit from multidisciplinary treatment concepts including tyrosine kinase inhibitors. Due to its complexity, management of thyroid cancer patients should be performed in close collaboration with a specialized thyroid cancer team.
authors: Klinik für Endokrinologie und Stoffwechselerkrankungen, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland, vera.tiedje@uk-essen.de.
authors: V
authors: V
authors: Tiedje
authors: K W
authors: KW
authors: Schmid
authors: F
authors: F
authors: Weber
authors: A
authors: A
authors: Bockisch
authors: D
authors: D
authors: Führer
mesh_terms: D003131:Combined Modality Therapy / Q000379:methods; D019317:Evidence-Based Medicine; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000517:prevention & control*; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D013965:Thyroidectomy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals
references: Langenbecks Arch Surg. 2013 Mar;398(3):347-75
references: 23456424
references: N Engl J Med. 2013 Feb 14;368(7):684-5
references: 23406047
references: Nuklearmedizin. 2007;46(5):213-9
references: 17938757
references: Thyroid. 2013 May;23(5):600-4
references: 23113752
references: Dtsch Arztebl Int. 2012 Jul;109(29-30):506-15; quiz 516
references: 23008749
references: Thyroid. 2010 Dec;20(12):1341-9
references: 21034228
references: Thyroid. 2009 Nov;19(11):1167-214
references: 19860577
references: Cancer Res. 2011 Jul 1;71(13):4403-11
references: 21596819
references: J Clin Oncol. 2013 Oct 10;31(29):3639-46
references: 24002501
references: Eur J Endocrinol. 2006 Jun;154(6):787-803
references: 16728537
references: J Clin Endocrinol Metab. 2006 Aug;91(8):2892-9
references: 16684830
references: N Engl J Med. 2013 Feb 14;368(7):623-32
references: 23406027
references: Lancet. 2013 Mar 23;381(9871):1058-69
references: 23668556
references: World J Surg Oncol. 2013 Nov 14;11:291
references: 24228637
references: Nat Clin Pract Endocrinol Metab. 2007 Sep;3(9):641-50
references: 17710085
references: J Clin Endocrinol Metab. 2013 Jan;98(1):31-42
references: 23185034
references: Lancet. 2013 Mar 23;381(9871):1046-57
references: 23668555
references: World J Surg. 2006 Jun;30(6):1088-95
references: 16736341
references: J Clin Oncol. 2015 Jul 10;33(20):e84-7
references: 24687827
references: Thyroid. 2012 Nov;22(11):1104-39
references: 23130564
references: BMC Cancer. 2011 Aug 11;11:349
references: 21834960
references: Thyroid. 2014 Feb;24(2):232-40
references: 23721245
references: J Clin Endocrinol Metab. 2014 May;99(5):1543-55
references: 24423326
references: Clin Invest Med. 2012 Jun 01;35(3):E152-6
references: 22673318
references: Ann Surg. 2011 Oct;254(4):653-60
references: 21876434